Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).

被引：0
|
作者：
Schonhoft, Joseph
Gill, Audrey
Graf, Ryon P.
Jendrisak, Adam
Barnett, Ethan
Benoliel, Hannah
Carbone, Emily
Tubbs, Alisa
Orr, Sarah
Byun, Jiyun
Wenstrup, Rick
Scher, Howard, I
机构：
[1] Epic Sci Inc, San Diego, CA USA
[2] Epic Sci, San Diego, CA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5571
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel
    Yokom, Daniel W.
    Stewart, John
    Alimohamed, Nimira S.
    Winquist, Eric
    Berry, Scott
    Hubay, Stacey
    Lattouf, Jean-Baptiste
    Leonard, Helene
    Girolametto, Carla
    Saad, Fred
    Sridhar, Srikala S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2018, 12 (08): : E365 - E372
  • [42] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [43] Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Scher, H.
    Graf, R.
    Schreiber, N.
    Lu, D.
    Louw, J.
    Alvarez, H. A. Vargas
    Bambury, R.
    Danila, D.
    McLaughlin, B.
    Heller, G.
    Fleisher, M.
    Dittamore, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Prognostic factors for non-metastatic castration-resistant prostate cancer treated with androgen receptor signaling inhibitors
    Takahara, Kiyoshi
    Naiki, Taku
    Nakane, Keita
    Watanabe, Hiromitsu
    Miyake, Hideaki
    Koie, Takuya
    Yasui, Takahiro
    Shiroki, Ryoichi
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 21 (04)
  • [45] DETECTION OF AR-V7 TRANSCRIPTS IN WHOLE BLOOD RNA OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Kwan, Edmond M.
    To, Sarah
    Fettke, Heidi
    Docanto, Maria
    Martelotto, Luciano
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 50 - 50
  • [46] Screening and baseline analysis of circulating tumor cell (CTC) counts and androgen receptor (AR) localization with clinical characteristics of men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY
    Tagawa, S. T.
    Galletti, G.
    Antonarakis, E. S.
    Tasaki, S.
    Gjyrezi, A.
    Worroll, D.
    Portella, L.
    Kirby, B. J.
    Stewart, J.
    Zaher, A.
    Saad, F.
    Vanhuyse, M.
    Suri, S.
    Lannin, T. B.
    Gruber, C.
    Pratt, E.
    North, S.
    Eisenberger, M. A.
    Nanus, D. M.
    Giannakakou, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S498 - S499
  • [47] Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer
    Bitting, Rhonda L.
    Healy, Patrick
    Halabi, Susan
    George, Daniel J.
    Goodin, Michael
    Armstrong, Andrew J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (03) : 110.e1 - 110.e9
  • [48] Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC).
    Keegan, Niamh M.
    Arfe, Andrea
    Barnett, Ethan
    Cohn, Erica Dayan
    Zhao, Jimmy
    Carbone, Emily
    Zanone, Michelle
    Anderson, Amanda
    Wenstrup, Rick
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.
    Kim, Won
    Small, Eric Jay
    Aggarwal, Rahul Raj
    Den, Robert Benjamin
    Lehrer, Jonathan
    Zhang, Li
    Youngren, Jack
    Goldstein, Theodore C.
    Alumkal, Joshi J.
    Gleave, Martin
    Rettig, Matthew
    Evans, Christopher P.
    Beer, Tomasz M.
    Reiter, Robert Evan
    Huang, Jiaoti
    Thomas, George V.
    Davicioni, Elai
    Ryan, Charles J.
    Spratt, Daniel Eidelberg
    Feng, Felix Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223
    Al-Ezzi, E. M. M.
    Alqaisi, H. A.
    Iafolla, M.
    Sridhar, S.
    Sacher, A.
    Fallah-Rad, N.
    Jiang, D. M.
    Catton, C.
    Warde, P.
    Hamilton, R.
    Fleshner, N.
    Zlotta, A.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S537 - S538
12345